Tag:
Silenor
Latest Headlines
Latest Headlines
Somaxon to axe HQ staffers as adviser explores possible sale
Plagued by weak sales of the sleep drug Silenor , San Diego-based Somaxon ( $SOMX ) laid out plans to lay off a majority of its headquarters staff as a financial adviser reviews its options, including a
Somaxon buoyed by FDA word on OTC Silenor
Somaxon Pharmaceuticals sees a way forward with its sleep drug Silenor. The drug is a branded version of the long-generic antidepressant doxepin, so it's no surprise that generic rivals are already
Somaxon (finally) wins FDA approval for sleep drug Silenor
San Diego-based Somaxon has won FDA approval of its sleep drug Silenor, completing a long and financially exhausting quest that has consumed more than $170 million. The third time proved the charm
Who's up for a big FDA approval decision in the first half?
Few events can move a biotech stock quite like an FDA decision on a new drug app. And given the agency's rep for somewhat unpredictable behavior, there's no such thing as a sure thing. All of which
Somaxon tries again with Silenor
Somaxon Pharmaceuticals said today that it has resubmitted data for its sleep drug Silenor to the FDA, making it the company's third go-around with the agency. The drug was first rejected in early
Somaxon shares plunge on second FDA rejection
San Diego-based Somaxon Pharmaceuticals' second time around with its NDA for the insomnia drug Silenor proved no more successful than the first, and its stock plunged 65 percent on the FDA's renewed
Somaxon decides next move after FDA rejection
Somaxon has met with the FDA to decide its next steps following the rejection of its sleep drug Silenor. In February, the agency said it wouldn't approve the drug without more data, thought it didn't
FDA denies approval for Somaxon sleep drug
The FDA has struck a blow to Somaxon Pharmaceuticals, saying it can't provide an approval for its sleep therapy Silenor without more data. According to Somaxon, the "raised a number of issues
Insomnia market attracts drug developers
The market for insomnia drugs in the U.S. is growing at a whopping 29 percent per year, hitting $4.6 billion in 2006 and attracting the attention of a wide range of drug developers. More than a
